Over the last 12 months, Alkermes insiders reported no purchases and 9 sales totaling $4.6M across SEC Form 4 filings. 78% of the activity was filed under pre-arranged 10b5-1 trading plans.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | snyderman nancy lynn MDD | ▼ Sale | 44,472 | $50.35 | $2.2M | -74.3% | — |
| Aug 3, 2026 | Hopkinson Craig C.EVP R&D, Chief Medical Officer · O | ▼ Sale | 9,000 | $48.58 | $437K | -11.5% | plan |
| Aug 3, 2026 | Gaffin David JosephEVP, CLO, Alkermes, Inc. · O | ▼ Sale | 2,034 | $48.58 | $99K | -0.9% | plan |
| Jul 6, 2026 | Gaffin David JosephEVP, CLO, Alkermes, Inc. · O | ▼ Sale | 2,034 | $54.03 | $110K | -0.9% | plan |
| Jul 1, 2026 | Hopkinson Craig C.EVP R&D, Chief Medical Officer · O | ▼ Sale | 9,000 | $51.51 | $464K | -10.9% | plan · 2 tranches |
| Jun 12, 2026 | Wright Christopher ID | ▼ Sale | 2,000 | $45.1 | $90K | -7.2% | plan |
| Jun 4, 2026 | Gaffin David JosephEVP, CLO, Alkermes, Inc. · O | ▼ Sale | 2,034 | $43.05 | $88K | -0.9% | plan |
| Jun 1, 2026 | Hopkinson Craig C.EVP R&D, Chief Medical Officer · O | ▼ Sale | 9,000 | $41.67 | $375K | -10.4% | plan |
| May 29, 2026 | Parisi Samuel JosephVP, Finance (Interim PAO) · O | ▼ Sale | 16,217 | $42.36 | $687K | -67.8% | — |
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ALKS feed.